BIOGEN

Health Issues

Discussions regarding drug pricing and supply chain issues, rare diseases, gene therapy and value based arrangements; biosimilar support; Alzheimer's policy, PET scan coverage and reimbursement, and dementia care H.R.19, Lower Costs, More Cures Act of 2021 H.R. 5376, Inflation Reduction Act (Build Back Better Act), including provisions related to corporate taxes, Medicare, and prescription drug pricing H.R.7667, Food and Drug Amendments of 2022 User Fee Agreements, specifically reauthorization of PDUFA and BSUFA Aduhelm National Coverage Determination

TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)

Medicare/Medicaid

Issues regarding coverage, coding, and reimbursement issues Issues regarding Alzheimer's treatments

TargetedSENATE · HOUSE OF REPRESENTATIVES · Centers For Medicare and Medicaid Services (CMS)

Pharmacy

H.R.3/S.2543, Elijah E. Cummings Lower Drug Costs Now Act, discussions regarding support to increase Part B biosimilar payments from ASP +6% to ASP +8% of the reference product Issue regarding COVID-19, supply chain, pharmaceutical pricing and drug development lifecycle